

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT7960186

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ACKNOWLEDGEMENT OF RIGHTS
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
TEVA PHARMACEUTICAL INDUSTRIES LTD.	07/24/2017
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	ASSIA CHEMICAL INDUSTRIES LTD.
<b>Street Address:</b>	2 DENMARK STREET
<b>City:</b>	PETACH TIKVA
<b>State/Country:</b>	ISRAEL
<b>Postal Code:</b>	49517
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
Application Number:	17570502
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(860)286-0115
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	8602862929
<b>Email:</b>	usptopatentmail@cantorcolburn.com
<b>Correspondent Name:</b>	CANTOR COLBURN LLP
<b>Address Line 1:</b>	20 CHURCH STREET
<b>Address Line 2:</b>	22ND FLOOR
<b>Address Line 4:</b>	HARTFORD, CONNECTICUT 06103
<b>ATTORNEY DOCKET NUMBER:</b>	APH0673US6C
<b>NAME OF SUBMITTER:</b>	ROBERTA L. PELLETIER
<b>SIGNATURE:</b>	/Roberta L. Pelletier/
<b>DATE SIGNED:</b>	05/18/2023
<b>Total Attachments: 1</b> source=96D5335#page1.tif	

ACKNOWLEDGEMENT OF RIGHTS

WHEREAS TEVA PHARMACEUTICAL INDUSTRIES LTD., having a place of business at 5 BASEL STREET, P.O. BOX 3190, PETAH TIQVA, ISRAEL 49131, hereinafter called "Teva," has performed research and development activities for and on behalf of Assia Chemical Industries Ltd., having a place of business at 2 Denmark Street, 49517 Petach Tikva, Israel, hereinafter called "Applicant," which have led to the inventions and discoveries in **ADD TITLE OF PCT HERE**, described in an International Patent Application that is being filed in the United States Receiving Office, and which has been assigned internal reference number PTV152-PCT (APH0673PCT), and

WHEREAS Applicant is the owner of all title, rights, benefits, and privileges in and to said inventions and discoveries pursuant to the Services Agreement between Teva and Applicant, dated no later than the filing date of the International Patent Application, identified above ("the Agreement").

NOW, THEREFORE, Teva hereby, without reservation, acknowledges and confirms:

1. that pursuant to the Agreement, Applicant is the owner of the entire right, title, and interest, including any right to claim priority, in and to said inventions and discoveries worldwide, and in and to any patent(s) that may issue for said inventions and discoveries; and
2. Applicant has the right to file, under any International Convention or otherwise, for patent protection for said inventions and discoveries.

TEVA PHARMACEUTICAL INDUSTRIES LTD.

Signature:

*Liat Stolarsky*

Date:

*July 24, 2017*

Name of Person Signing:

*Liat Stolarsky*

Title of Person Signing:

*Dir Assoc Gen Patent Counsel*

Signature:

*Sharon F. Hausdorff*

Date:

*July 24, 2017*

Name of Person Signing:

Sharon F. Hausdorff, Ph.D.  
VP and General Patent Counsel  
Global Specialty and InnoTech

Title of Person Signing: